Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 in Recurrent/Progressive High-grade Glioma
NCT06763965Phase 2Enrolling by invitation
- Sponsor
- Beijing Bio-Targeting Therapeutics
- Start
- Nov 2024
- Primary completion
- Jul 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of BioTTT001 in glioma, sponsored by Beijing Bio-Targeting Therapeutics. Started Nov 2024; status: enrolling by invitation.
02
Drugs
BioTTT001
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06763965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763965.